1R. P. Abratt,P. A. Willcox,R. H. Hewitson. Etoposide combination therapy for small cell carcinoma of the lung[J] 1987,Cancer Chemotherapy and Pharmacology(1):83～84
5Vaidyanathan S, Boroujerdi M. Interaction of dexrazoxane with red blood cells and hemnoglobin alters pharmacokineties of doxorubicin.Cancer Chemother Pharmacol,2000,46(2) :93-100
6Kolaric K, Bradamante V, Cervek J, et al. A p hase Ⅱ trial of cardioproteetion with Cardioxane (ICRF-187) in patients with advanced breast cancer receiving 5-fluorouracil, doxorubicin and cyclophosphamide. Oncology, 1995,52 (3): 251
7Seymour L, Bramwell V, Moran LA. Use of dexrazoxane as a cardioproteetant in patients receiving doxorubicin or epirubicin cheotherapy for the treatment ofcancer. Cancer Prev Control, 1999,3(2): 145-159
8Wahab MH,Akoul ES,Abdel-Aziz AA. Modulatory effects of melatonin and vitamin E on doxorubicin-induced cardiotoxicity in Ehrlich ascites carcinoma-bearing mice. Ttmori,2000,86(2): 157-162
9Wakasugi S. Drug-induced myocardial disease-adriarnycin cardiotoxicity. Nippon Rinsho,2000,58(1 ) :204-211
10Vaidyanathan S,Boroujerdi M. Effect of tamoxifen pretreatment on the pharmacokineties, metabolism and cardiotoxicity of doxorubicin in female rats. CancerChemother Pharmacol, 2000,46(3 ): 185-192
